<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: This study sought to examine whether <z:chebi fb="1" ids="6495">lipoprotein</z:chebi>(a) levels predict coronary artery lumen changes in patients with symptomatic <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (CAD) and <z:mpath ids='MPATH_458'>normal</z:mpath> to moderate <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>BACKGROUND: Recent conflicting reports have confirmed or refuted the association of <z:chebi fb="1" ids="6495">lipoprotein</z:chebi>(a) with clinical events or angiographically verified disease progression </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The association between serum <z:chebi fb="1" ids="6495">lipoprotein</z:chebi>(a) and changes in coronary artery lumen was studied in 704 men entered into the Regression Growth Evaluation <z:chebi fb="0" ids="35664">Statin</z:chebi> Study (REGRESS), a double-blind, placebo-controlled, quantitative angiographic study that assessed the effect of 2 years of pravastatin treatment </plain></SENT>
<SENT sid="3" pm="."><plain>The primary end points were changes in average mean segment diameter (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e>) and average minimal obstruction diameter (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MOD</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>Pravastatin- and placebo-treated patients were classified as having progressing, regressing or stable CAD, and median <z:chebi fb="1" ids="6495">lipoprotein</z:chebi>(a) concentrations were compared </plain></SENT>
<SENT sid="5" pm="."><plain>Bivariate and multivariate regression analyses were performed in the overall patient group and in high risk subgroups </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Pravastatin treatment did not affect serum <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi>(a) levels </plain></SENT>
<SENT sid="7" pm="."><plain>Median in-trial (sampled at 24 months) <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi>(a) levels for regressing, stable and progressing CAD were, respectively, 130, 162 and 251 U/liter in placebo-treated patients and 143, 224 and 306 U/liter in pravastatin-treated patients </plain></SENT>
<SENT sid="8" pm="."><plain>Predictors of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MOD</z:e> changes were baseline <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MOD</z:e>, in-trial <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi>(a), in-trial <z:chebi fb="6" ids="39025">high density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>) cholesterol and baseline use of long-acting nitrates </plain></SENT>
<SENT sid="9" pm="."><plain>The multivariate models predicted 14% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> changes and 12% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MOD</z:e> changes; <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi>(a) predicted only 2.6% and 4.8%, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>However, in patients with in-trial <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> levels &lt;0.7 mmol/liter, <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi>(a) predicted up to 37% of the arteriographic changes </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Serum <z:chebi fb="1" ids="6495">lipoprotein</z:chebi>(a) levels predict coronary artery lumen changes in <z:mpath ids='MPATH_458'>normal</z:mpath> to moderately hypercholesterolemic white men with CAD; its atherogenicity is marked in the presence of concomitant <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypoalphalipoproteinemia</z:e> </plain></SENT>
</text></document>